Sara Rattik

Title: Sara Rattik: Innovator in Antibody Development

Introduction

Sara Rattik is a prominent inventor based in Åkarp, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. With a total of two patents to her name, Rattik is recognized for her innovative work in the treatment of diseases associated with interleukin-1 receptor accessory protein (IL1RAP).

Latest Patents

Rattik's latest patents focus on the Anti-IL1RAP antibody. This invention relates to an antibody or antigen-binding fragment that specifically binds to IL1RAP. The patent also includes a polynucleotide encoding the antibody, a vector containing the polynucleotide, and a recombinant host cell that incorporates the polynucleotide or vector. Furthermore, the invention outlines a method for producing the antibody or antigen-binding fragment. The composition described in the patent is intended for use in medicine, particularly for the prevention, treatment, alleviation, detection, and diagnosis of diseases linked to IL-1α, IL-1β, IL-33, IL-36α, IL-36β, and IL-36γ signaling.

Career Highlights

Sara Rattik is currently employed at Cantargia AB, a company dedicated to developing innovative treatments for cancer and other serious diseases. Her work at Cantargia has positioned her as a key player in the biotechnology sector, contributing to advancements in therapeutic antibody development.

Collaborations

Rattik collaborates with notable colleagues, including David Liberg and Camilla Rydberg Millrud. These partnerships enhance her research and development efforts, fostering innovation in the field.

Conclusion

Sara Rattik's contributions to antibody development exemplify her commitment to advancing medical science. Her innovative patents and collaborative efforts position her as a significant figure in biotechnology.